177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
1. 请及时下载文件确认是否正确, 系统将在 2026-04-09 13:27:01 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S0140-6736(24)01653-2
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0140673624016532
其他信息:
出版社: Elsevier BV
作者: Michael J Morris; Daniel Castellano; Ken Herrmann; Johann S de Bono; Neal D Shore; Kim N Chi; Michael Crosby; Josep M Piulats; Aude Fléchon; Xiao X Wei; Hakim Mahammedi; Guilhem Roubaud; Hana Študentová; James Nagarajah; Begoña Mellado; Álvaro Montesa-Pino; Euloge Kpamegan; Samson Ghebremariam; Teri N Kreisl; Celine Wilke; Katja Lehnhoff; Oliver Sartor; Karim Fizazi
